Hosted on MSN

How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye Disease

Viridian TherapeuticsVRDN shares skyrocketed Tuesday after the small biotech unveiled promising results for its experimental eye disease treatment, a potential rival to Amgen'sAMGN blockbuster, ...
Reuters

Viridian eye disease drug surpasses expectations in late-stage trial; shares soar

May 5 (Reuters) - Viridian Therapeutics (VRDN.O), opens new tab said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic ‌patients, sending its ...
FierceBiotech

Viridian’s Tepezza rival racks up second phase 3 win, clearing path to FDA

A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster ...
Healio

Veligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye disease

Please provide your email address to receive an email when new articles are posted on . Veligrotug improved proptosis, diplopia and clinical activity score in patients with active or chronic thyroid ...